Not available
Quote | Novartis AG (NYSE:NVS)
Last: | $106.13 |
---|---|
Change Percent: | 0.81% |
Open: | $106.35 |
Close: | $106.13 |
High: | $106.53 |
Low: | $105.72 |
Volume: | 1,683,022 |
Last Trade Date Time: | 07/19/2024 03:00:00 am |
News | Novartis AG (NYSE:NVS)
2024-07-21 07:00:00 ET More on AstraZeneca, Bristol-Myers, etc. Bristol-Myers Squibb - Investors Are Too Long-Term Focused Bristol-Myers Squibb Is A Bargain Now AstraZeneca Stock: Upgrading From 'Hold' To 'Buy' Ahead Of Q2 2024 Earnings Dividend Roundup: Gold...
2024-07-20 03:50:03 ET Summary The company continues to deliver strong turnover growth and core margin expansion. Ongoing buyback combined with a juicy dividend yield provides downside protection. Positive contributions from newer drug launches. Novartis raised the 2024 core o...
Message Board Posts | Novartis AG (NYSE:NVS)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $NVS News Article - Trading Novartis $NVS With Integrated Risk Controls | whytestocks | investorshangout | 03/10/2023 5:10:51 PM |
whytestocks: $NVS News Article - Erasca Announces Exclusive Worldwide License for Pan-RAF Inhibitor | whytestocks | investorshangout | 12/09/2022 1:25:46 PM |
Former Head of Novartis Respiratory and Allergy Medicine | subslover | investorshub | 05/25/2022 1:21:42 PM |
https://www.novartis.com/news/media-releases/new-novartis-data-demonstrate-only- | FACT-MASTER | investorshub | 05/04/2022 10:57:17 PM |
https://www.novartis.com/news/media-releases/novartis-kymriah-receives-ec-approv | FACT-MASTER | investorshub | 05/04/2022 10:56:02 PM |
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-18 16:45:16 ET Image source: The Motley Fool. Novartis Ag (NYSE: NVS) Q2 2024 Earnings Call Jul 18, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
2024-07-18 14:15:34 ET By most standards shares of drugmaker Novartis (NYSE: NVS) should be higher following this morning's release of its second-quarter results. The drugmaker's top and bottom lines were both better than expected, and up from year-earlier comparisons. And profit gu...